Sep 12, 2022 / 03:05PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Okay. Great. Thanks for joining us, everybody. I'm Terence Flynn, the pharma analyst at Morgan Stanley. I'm very pleased to have Arvinas with me today. And before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Thanks so much for joining us today. We have Randy Teel, who's Senior Vice President of Corporate and Business Development; and Ian Taylor, Chief Scientific Officer. Thanks so much both for being here today. Maybe Randy to start, I just thought given Arvinas is a pretty recent public company, you could provide kind of an overview of the company and the strategy. And then, Ian will go over to you for some more detailed questions in the pipeline. But thanks again for being here.
Randy Teel - Arvinas, Inc. - SVP of Corporate &
Arvinas Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers